AI assistant
Sending…
Kezar Life Sciences, Inc. — Director's Dealing 2018
Jun 27, 2018
34845_dirs_2018-06-27_74c75b33-7269-4f6a-bfdf-7fb3b22b6a3d.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Kezar Life Sciences, Inc. (KZR)
CIK: 0001645666
Period of Report: 2018-06-25
Reporting Person: Aberdare Management Company, LLC (10% Owner)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2018-06-25 | Common Stock | C | 105162 | — | Acquired | 105162 | Direct |
| 2018-06-25 | Common Stock | C | 31481 | — | Acquired | 136643 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2018-06-25 | Series A Convertible Preferred Stock | $ | C | 105162 | Disposed | Common Stock (105162) | Direct | |
| 2018-06-25 | Series B Convertible Preferred Stock | $ | C | 31481 | Disposed | Common Stock (31481) | Direct |
Footnotes
F1: Each share of Series A Convertible Preferred Stock and Series B Convertible Preferred Stock was convertible at any time, at the option of the holder, into Common Stock, on a one-for-one basis, had no expiration date and converted into shares of Common Stock upon the closing of the Issuer's initial public offering.
F2: The members of Aberdare Management Company, LLC are Paul H. Klingenstein and Kathleen R. Bole.
More from Kezar Life Sciences, Inc.
Delisting Announcement
2026
May 11
M&A Activity
2026
May 11
Interim / Quarterly Report
2026
May 11
Annual Report
2026
Apr 30
Legal Proceedings Report
2026
Apr 3
Merger & Acquisition
2026
Mar 30
M&A Activity
2026
Mar 30
Major Shareholding Notification
2026
Feb 9
Major Shareholding Notification
2025
Nov 14
Interim / Quarterly Report
2025
Nov 12